Document Detail


Association between blood spot transforming growth factor-β and patent ductus arteriosus in extremely low-birth weight infants.
MedLine Citation:
PMID:  22684193     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Permanent ductal closure involves anatomic remodeling, in which transforming growth factor (TGF)-β appears to play a role. Our objective was to evaluate the relationship, if any, between blood spot TGF-β on day 3 and day 7 of life and patent ductus arteriosus (PDA) in extremely low birth weight (ELBW) infants. Prospective observational study involving ELBW infants (n = 968) in the National Institute of Child Health and Human Development Neonatal Research Network who had TGF-β measured on filter paper spot blood samples using a Luminex assay. Infants with a PDA (n = 493) were significantly more immature, had lower birth weights, and had higher rates of respiratory distress syndrome than those without PDA (n = 475). TGF-β on days 3 and 7 of life, respectively, were significantly lower among neonates with PDA (median 1,177 pg/ml [range 642-1,896]; median 1,386 pg/ml [range 868-1,913]) compared with others without PDA (median 1,334 pg/ml [range 760-2,064]; median 1,712 pg/ml [range 1,014-2,518 pg/ml]). The significant difference persisted when death or PDA was considered a composite outcome. TGF-β levels were not significantly different among subgroups of infants with PDA who were not treated (n = 51) versus those who were treated medically (n = 283) or by surgical ligation (n = 159). TGF-β was not a significant predictor of death or PDA (day 3 odds ratio [OR] 0.99, 95 % confidence interval [CI] 0.83-1.17; day 7 OR 0.88, 95 % CI 0.74-1.04) on adjusted analyses. Our results suggest that blood spot TGF-β alone is unlikely to be a reliable biomarker of a clinically significant PDA or its responsiveness to treatment.
Authors:
Girija Natarajan; Seetha Shankaran; Scott A McDonald; Abhik Das; Richard A Ehrenkranz; Ronald N Goldberg; Barbara J Stoll; Jon E Tyson; Rosemary D Higgins; Diana Schendel; David M Hougaard; Kristin Skogstrand; Poul Thorsen; Waldemar A Carlo
Related Documents :
8384263 - Isolation and purification of aeromonas sobria cytotonic enterotoxin and beta-haemolysin.
22718603 - The impact of the time interval between two successive deliveries in an obstetric unit ...
11239653 - Mode of delivery and risk of respiratory diseases in newborns.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.     Date:  2012-06-10
Journal Detail:
Title:  Pediatric cardiology     Volume:  34     ISSN:  1432-1971     ISO Abbreviation:  Pediatr Cardiol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-14     Completed Date:  2013-07-03     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  8003849     Medline TA:  Pediatr Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  149-54     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI 48201, USA. gnatara@med.wayne.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Ductus Arteriosus, Patent / blood*,  complications
Female
Humans
Infant
Infant, Extremely Low Birth Weight / blood*
Infant, Newborn
Male
Prospective Studies
Respiratory Distress Syndrome, Newborn / blood,  epidemiology*
Transforming Growth Factor beta / blood*
Grant Support
ID/Acronym/Agency:
5 M01 RR00044/RR/NCRR NIH HHS; GCRC M01 RR 08084/RR/NCRR NIH HHS; GCRC M01 RR30/RR/NCRR NIH HHS; GCRC M01 RR32/RR/NCRR NIH HHS; GCRC M01 RR39/RR/NCRR NIH HHS; GCRC M01 RR6022/RR/NCRR NIH HHS; GCRC M01 RR633/RR/NCRR NIH HHS; GCRC M01 RR70/RR/NCRR NIH HHS; GCRC M01 RR7122/RR/NCRR NIH HHS; GCRC M01 RR750/RR/NCRR NIH HHS; GCRC M01 RR8084/RR/NCRR NIH HHS; GCRC M01 RR997/RR/NCRR NIH HHS; GCRC M01RR80/RR/NCRR NIH HHS; GCRCM01 RR16587/RR/NCRR NIH HHS; IAA Y1-HD-5000-01/HD/NICHD NIH HHS; M01 RR 00039/RR/NCRR NIH HHS; M01 RR 00070/RR/NCRR NIH HHS; M01 RR 00125/RR/NCRR NIH HHS; M01 RR 0039-43/RR/NCRR NIH HHS; M01 RR 00750/RR/NCRR NIH HHS; R03 HD054420/HD/NICHD NIH HHS; U01 HD36790/HD/NICHD NIH HHS; U10 HD 27871/HD/NICHD NIH HHS; U10 HD021385/HD/NICHD NIH HHS; U10 HD21364/HD/NICHD NIH HHS; U10 HD21373/HD/NICHD NIH HHS; U10 HD21385/HD/NICHD NIH HHS; U10 HD21397/HD/NICHD NIH HHS; U10 HD21415/HD/NICHD NIH HHS; U10 HD27851/HD/NICHD NIH HHS; U10 HD27853/HD/NICHD NIH HHS; U10 HD27856/HD/NICHD NIH HHS; U10 HD27871/HD/NICHD NIH HHS; U10 HD27880/HD/NICHD NIH HHS; U10 HD27881/HD/NICHD NIH HHS; U10 HD27904/HD/NICHD NIH HHS; U10 HD34216/HD/NICHD NIH HHS; U10 HD36790/HD/NICHD NIH HHS; U10 HD40461/HD/NICHD NIH HHS; U10 HD40492/HD/NICHD NIH HHS; U10 HD40498/HD/NICHD NIH HHS; U10 HD40521/HD/NICHD NIH HHS; U10 HD40689/HD/NICHD NIH HHS; U10HD40461/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Transforming Growth Factor beta
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combined Heart-Lung Transplantation: A Perspective on the Past and the Future.
Next Document:  Decreased Right Ventricular Function in Healthy Pediatric Cystic Fibrosis Patients Versus Non-Cystic...